Trial Visits
Official
Reports to the Ad Hoc Group
*
Working Paper concludes visit is potentially useful
# Working Paper concludes confidential information can be protected
Session |
Working Paper |
Submitted by |
Type of Facility |
Inspectors and Observers |
|
Session 21 Working Papers (BWC/AD HOC GROUP 54) |
Practice randomly-selected transparency visit to a biodefence facility 13 December 2000
* # |
Australia |
Biodefence Facility |
Australian team |
|
Session 19 Working Papers (BWC/AD HOC GROUP 51) |
Report on a trial transparency visit to a biological defensive facility
17 March 2000
* # |
Spain |
Biodefence Facility |
Spanish team (Ministries of Foreign Affairs, Health Education and Defence) |
|
Session 16 Working Papers (BWC/AD HOC GROUP 47) |
Report on two trial visits based on a transparency visit concept 24 August 1999 * # |
Germany |
Industrial Production Facility |
German team and a visiting team consisting of three people from three other States Parties |
|
Session 15 Working Papers (BWC/AD HOC GROUP 46) |
Report on a Trial Inspection (Random visit)
10 June 1999 * # |
Switzerland |
Industrial Production Facility |
Swiss team and a representative of the Ministry of Defence in Austria |
|
Session 13 Working Papers (BWC/AD HOC GROUP 44) |
Report of a National Trial Visit to a Vaccine and Serum Production Facility 14 January 1999 * # |
Islamic Republic of Iran |
Vaccine and Serum Production Facility |
Iranian team |
|
Session 12 Working Papers (BWC/AD HOC GROUP 43) |
Report on an international trial random visit 23 September 1998 * # |
Austria |
Pharmaceutical Facility |
Austrian team and visiting team consisting of four representatives from Japan, Germany and Switzerland |
|
Session 12 Working Papers (BWC/AD HOC GROUP 43) |
Report of a trial random visit to a biopharmaceutical production facility 21 August 1998 * # |
Denmark, Finland, Iceland, Norway and Sweden |
Biopharmaceutical Production Facility |
Home team (government representatives, technical experts and representatives of the facility) and a visiting team consisting of five persons from three other countries |
|
Session 9 Working Papers (BWC/AD HOC GROUP 39) |
Report of a visit to a Pharmaceutical Research Facility 09 January 1998 * # |
United Kingdom |
Pharmaceutical Research Facility |
Home team |
|
Session 9 Working Papers (BWC/AD HOC GROUP 39) |
Use of a simulated declaration format in a practice visit 17 December 1997 * |
United Kingdom |
Industrial Facility |
Home team |
|
Session 4 Working Papers (BWC/AD HOC GROUP 31) |
Trial inspection of a biological production facility
18 July 1996 * # |
Australia |
Biological Production Facility |
Australian inspection team |
|
Session 4 Working Papers (BWC/AD HOC GROUP 31) |
Report of a joint UK/Brazil practice non-challenge visit 18 July 1996 * # |
Brazil and the United Kingdom |
Vaccine and Serum Production Facility |
Brazilian and UK teams and an additional representative of PAHO (Pan American Health Organization) |